Skip to main content

Shares of Accelr8 Jump 40 Percent

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Accelr8 Technology were up around 41 percent in heavy trade Thursday afternoon on the NYSE Amex.

The Denver-based firm didn't report any news or file any documents with the US Securities and Exchange Commission during the last couple of days. However, on Monday it filed an 8-K with the SEC disclosing that its technology evaluation agreement with Novartis Vaccines and Diagnostics for the firm's BACcel rapid bacterial diagnostic system has been extended to June 30, 2011.

Accelr8 said in the filing that as of Jan. 31, it has received an aggregate amount of roughly $640,000 from Novartis, and it anticipates receiving "not less than $140,000 more pursuant to these agreements."

Accekr8's shares have nearly tripled since the beginning of the year — rising from a $.99 close on Dec. 31, 2011, to $2.84 this afternoon. They had traded as high as $3.19 earlier in the day. Trading volume today also was very heavy for the shares at around 918,000 versus an average daily volume of less than 23,000 for the preceding three months.

Accelr8's stock had struggled since late September 2009, when it announced that Becton Dickinson has declined an option to license the BACcel system. The option would have provided an exclusive license to BD to develop and sell a clinical diagnostic system for infectious diseases based on the platform, with Accelr8 retaining rights to all other commercial applications.

Since that time, Accelr8 has been cautioned by NYSE Amex that it could be delisted if it did not come into compliance with certain regulations regarding stockholder equity.

In December, the firm posted a first-quarter profit of $67,250, or $.01 per share, on revenues of $466,362.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.